An Open Letter to the Canadian Hemophilia Community on the Continued Availability of Eloctate® and Alprolix®
Learn moreOur scientists brought the first major advances in hemophilia treatment in nearly two decades, and we’re committed to developing new, life-changing medicines for people with rare blood disorders.
Learn moreWorking in partnership with patients, physicians, caregivers, and advocates, we aim to improve access to treatment, advance disease understanding and transform lives.
Learn moreCold Agglutinin Disease Associated with Greater Than Twofold Increased Risk of Mortality in First Five Years After Diagnosis
Read more